Fauna Bio signs collaboration with Lilly to leverage understandings from hibernation to discover novel obesity targets

blonca9
Dec 22, 2023
1 min read

Co-Founder & CEO Ashley Zehnder describes how Fauna studies animals that have disease resistance and how the company leverages understandings from this to tackle human disease. On Thursday, Fauna signed a deal with Eli Lilly worth up to $494 million to collaborate on obesity targets.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Fauna Bio signs collaboration with Lilly to leverage understandings from hibernation to discover novel obesity targets

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight